In-Person Access Only | 4.50 Earn CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The First Annual DEBATING LUNG Symposium will bring together nationally recognized thoracic oncology experts for a dynamic, evidence-based exploration of the most controversial and practice-changing topics in lung cancer care. Through a series of structured debates, faculty will present opposing perspectives on evolving standards of care, emerging therapeutics, biomarker-driven treatment strategies, multidisciplinary management, and future directions in thoracic oncology. Designed to challenge conventional thinking and encourage meaningful discussion, the symposium will provide attendees with balanced insights and practical approaches for integrating the latest clinical evidence into everyday practice.
Conference Agenda
Friday, February 12, 2027
Program Chairs:
Chadi Nabhan, MD, MBA, FACP and Bruna Pellini, MD
3:00 - 4:00 PM
Arrival, Networking, and Registration
4:00 - 5:30 PM
Breakout Focus Groups
5:30 - 6:30 PM
Networking Reception
7:00 - 9:00 PM
Faculty Dinner
Saturday, February 13, 2027
7:00 - 7:30 AM
Arrival, Breakfast, and Registration
7:35 - 8:20 AM
NON-CME Breakfast
Early Stage
8:50 AM - 9:20 AM
Debate 1: Adaura or Neo-Adaura in early stage EGFR+ NSCLC?
ADAURA:
Jonathan Wesley Riess, MD, MS | UC Davis Health
NEO-ADAURA:
Lyudmila Bazhenova, MD | UC San Diego Health
9:20 AM - 9:50 AM
Debate 2: MRD in early-stage Lung Cancer is ready for primetime
Yes:
Bruna Pellini, MD | Baptist Health
No:
Ticiana Leal, MD | Emory Winship Cancer Institute
9:50 AM - 10:20 AM
Debate 3: Should Every Resectable Stage II–III NSCLC Patient Receive Perioperative Immunotherapy?
YES: Perioperative immunotherapy should become the default -
Millie Das, MD | Stanford Medicine
NO: Many patients are overtreated -
Angel Qin, MD | University of Michigan Health
10:20 AM - 10:35 AM
Snack and Coffee Break
Advanced Stage
10:35 AM - 11:05 AM
Debate 4: The Future is in RAS-Targeting in NSCLCA
Yes:
Deborah Doroshow, MD, PhD | Mount Sinai
It’s just another marker:
Narjust Florez, MD | Dana-Farber Cancer Institute
11:05 AM - 11:35 AM
Debate 5: Liquid Biopsy is a must in all patients with NSCLCA
Yes:
David Gandara, MD | UC Davis Health
No:
Nagla Karim, MD | George Washington University
11:35 AM - 12:05 PM
Debate 6: MARIPOSA or FLAURA-2
MARIPOSA
Eric Singhi, MD | UT MD Anderson
FLAURA-2
Heather Wakelee, MD | Stanford Medicine
12:05 PM - 12:35 PM
NON-CME Lunch
12:35 PM - 1:20 PM
NON-CME Lunch
1:20 PM - 1:50 PM
Networking, Housekeeping Notes and Survey
Future Directions
1:50 PM - 2:20 PM
Debate 7: ADCs replacing chemotherapy by 2030
Yes:
Misako Nagasaka, MD | UCI Health
No:
Hossein Borghaei, DO, MS |Fox Chase Cancer Center
2:20 PM - 2:50 PM
Debate 8: Is molecular profiling ready for routine clinical use in SCLC?
Yes:
Ravi Salgia, MD | City of Hope
No:
Gilberto Lopes, MD | University of Miami
2:50 PM
Concluding Remarks
3:00 PM - 4:30 PM
Sponsored Focus Group Opportunities
4:40 PM
ADJOURN
Agenda Subject To Change. All times are PST.
-
-
-
Complimentary registration for healthcare professionals
Expert debates addressing today's most controversial topics in lung cancer
Balanced, evidence-based perspectives from nationally recognized thoracic oncology leaders
Practical clinical insights to support real-world treatment decision-making
Interactive discussion and networking with faculty, peers, and industry partners
The latest advances in lung cancer research, precision medicine, and emerging therapeutic strategies